English

C4 Therapeutics, Inc.

EDGAR

CCCC Quarterly report (10-Q) · filed 2026-08-11

Annual consolidated revenue for 2025: about USD 35.95M, using the latest reported figures. The previous period, 2024, was about USD 35.58M.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

6.64 million USD

2026 Q2 · USD

Exact inputs and evidence

Revenue: 6641000 USD Source

Operating margin

-397.88%

2026 Q2 · %

Exact inputs and evidence

Operating Income: -26423000 USD Source
Revenue: 6641000 USD Source

Operating cash flow

-1.57 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -31518000 USD Source
Operating Cash Flow: -29944000 USD Source

Free cash flow

-1.61 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -31518000 USD Source
Operating Cash Flow: -29944000 USD Source
Capital Expenditure: 101000 USD Source
Capital Expenditure: 64000 USD Source

Cash and cash equivalents: 78.6 million USD 2026-06-30 Source
Exact value

78610000 USD
Long-term debt including current maturities: 10.3 million USD 2023-06-30 Source
Exact value

10335000 USD
Shares outstanding: 123 million shares 2026-06-30 Source
Exact value

122905756 shares

Reported share-count change

73.09% · 51.9 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

71007083 shares · 2025-06-30· Source
122905756 shares · 2026-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

35 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Revenue: 11230000 USD · 2025-07-01 – 2025-09-30 Source
Revenue: 35947000 USD · 2025-01-01 – 2025-12-31 Source
Revenue: 24931000 USD · 2025-01-01 – 2025-09-30 Source
Revenue: 6152000 USD · 2026-01-01 – 2026-03-31 Source
Revenue: 6641000 USD · 2026-04-01 – 2026-06-30 Source

Net income

-101 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Net income: -32166000 USD · 2025-07-01 – 2025-09-30 Source
Net income: -104994000 USD · 2025-01-01 – 2025-12-31 Source
Net income: -84508000 USD · 2025-01-01 – 2025-09-30 Source
Net income: -25129000 USD · 2026-01-01 – 2026-03-31 Source
Net income: -23635000 USD · 2026-04-01 – 2026-06-30 Source

Operating cash flow

-84.9 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -76549000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -45342000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -98694000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -76549000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -29944000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -31518000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -29944000 USD · 2026-01-01 – 2026-03-31 Source

Capital expenditure

523 thousand USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Capital expenditure: 596000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 185000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 607000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 596000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 64000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 101000 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 64000 USD · 2026-01-01 – 2026-03-31 Source

Free cash flow

-85.4 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -76549000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -45342000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -98694000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -76549000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -29944000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -31518000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -29944000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 596000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 185000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 607000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 596000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 64000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 101000 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 64000 USD · 2026-01-01 – 2026-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-08-11.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 5 of 11 periods available· newest 2025-12-31
Operating income: 7 of 11 periods available· newest 2025-12-31
Net income: 7 of 11 periods available· newest 2025-12-31
Operating cash flow: 7 of 11 periods available· newest 2025-12-31
Capital expenditure: 7 of 11 periods available· newest 2025-12-31
Total assets: 5 of 11 periods available· newest 2025-12-31
Total liabilities: 5 of 11 periods available· newest 2025-12-31
Current assets: 5 of 11 periods available· newest 2025-12-31
Current liabilities: 5 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 5 of 11 periods available· newest 2025-12-31
Long-term debt including current maturities: 2 of 11 periods available· newest 2022-12-31
Shares outstanding: 5 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+1%

Prior period

USD 35.58 million

2024-01-01 – 2024-12-31
Current period

USD 35.95 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

35947000 − 35584000 = 363000 USD

35584000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
35947000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · C4 Therapeutics, Inc. · 2025-12-31 C4 Therapeutics, Inc. (edgar:1662579) Year-over-year change in Revenue: 363000 USD Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T12:03:03Z Snapshot: 45a5b5ed28cca2766bb4405f888912c04c359bf1a8b2472edf40c372df5cfffc Dimensions: Consolidated View: https://fundies.io/companies/edgar/1662579?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 35947000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662579/000162828026012000/cccc-20251231.htm#1688965 Filing: 000162828026012000 Input fundies:Revenue: 35584000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662579/000162828026012000/cccc-20251231.htm#1689939 Filing: 000162828026012000
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 322,000

Prior period

−USD 105.32 million

2024-01-01 – 2024-12-31
Current period

−USD 104.99 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-104994000 − -105316000 = 322000 USD

-105316000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-104994000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · C4 Therapeutics, Inc. · 2025-12-31 C4 Therapeutics, Inc. (edgar:1662579) Year-over-year change in Net income: 322000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T12:03:03Z Snapshot: 45a5b5ed28cca2766bb4405f888912c04c359bf1a8b2472edf40c372df5cfffc Dimensions: Consolidated View: https://fundies.io/companies/edgar/1662579?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -104994000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662579/000162828026012000/cccc-20251231.htm#1988493 Filing: 000162828026012000 Input fundies:NetIncome: -105316000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662579/000162828026012000/cccc-20251231.htm#1989267 Filing: 000162828026012000
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 33.54 million

Prior period

−USD 65.16 million

2024-01-01 – 2024-12-31
Current period

−USD 98.69 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-98694000 − -65157000 = -33537000 USD

-65157000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-98694000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · C4 Therapeutics, Inc. · 2025-12-31 C4 Therapeutics, Inc. (edgar:1662579) Year-over-year change in Operating cash flow: -33537000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T12:03:03Z Snapshot: 45a5b5ed28cca2766bb4405f888912c04c359bf1a8b2472edf40c372df5cfffc Dimensions: Consolidated View: https://fundies.io/companies/edgar/1662579?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -98694000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662579/000162828026012000/cccc-20251231.htm#1304410 Filing: 000162828026012000 Input fundies:OperatingCashFlow: -65157000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662579/000162828026012000/cccc-20251231.htm#1305062 Filing: 000162828026012000
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+237.2%

Prior period

USD 180,000

2024-01-01 – 2024-12-31
Current period

USD 607,000

2025-01-01 – 2025-12-31

Exact inputs and evidence

607000 − 180000 = 427000 USD

180000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
607000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · C4 Therapeutics, Inc. · 2025-12-31 C4 Therapeutics, Inc. (edgar:1662579) Year-over-year change in Capital expenditure: 427000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T12:03:03Z Snapshot: 45a5b5ed28cca2766bb4405f888912c04c359bf1a8b2472edf40c372df5cfffc Dimensions: Consolidated View: https://fundies.io/companies/edgar/1662579?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 607000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662579/000162828026012000/cccc-20251231.htm#1309902 Filing: 000162828026012000 Input fundies:CapitalExpenditure: 180000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662579/000162828026012000/cccc-20251231.htm#1310461 Filing: 000162828026012000
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue USD 35.95 million 100% of revenue
Operating costs Derived USD 151.17 million 421% of revenue
Operating income −USD 115.22 million −321% of revenue
Tax, interest and other Derived −USD 10.23 million −28% of revenue
Net income −USD 104.99 million −292% of revenue

Cash

Operating cash flow −USD 98.69 million −275% of revenue
Capital expenditure USD 607,000 1.7% of revenue
Free cash flow Derived −USD 99.3 million −276% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2021 Operating loss: operating costs were 279% of revenue.
2022 Operating loss: operating costs were 517% of revenue.
2023 Operating loss: operating costs were 770% of revenue.
2024 Operating loss: operating costs were 436% of revenue.
2025 Operating loss: operating costs were 421% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2021 2021-01-01 – 2021-12-31	45785000	127919000 Derived	-82134000	1758000 Derived	-83892000	-88242000 Derived	Source 2021-01-01 – 2021-12-31: 45785000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -82134000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -83892000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -86965000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 1277000 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	31096000	160630000 Derived	-129534000	-1359000 Derived	-128175000	-111435000 Derived	Source 2022-01-01 – 2022-12-31: 31096000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -129534000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -128175000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -105939000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 5496000 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	20756000	159787000 Derived	-139031000	-6538000 Derived	-132493000	-108546000 Derived	Source 2023-01-01 – 2023-12-31: 20756000 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -139031000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -132493000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -106838000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 1708000 USD Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	35584000	155198000 Derived	-119614000	-14298000 Derived	-105316000	-65337000 Derived	Source 2024-01-01 – 2024-12-31: 35584000 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -119614000 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -105316000 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: -65157000 USD Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 180000 USD Inspect Capital Expenditure Open source
2025 2025-01-01 – 2025-12-31	35947000	151169000 Derived	-115222000	-10228000 Derived	-104994000	-99301000 Derived	Source 2025-01-01 – 2025-12-31: 35947000 USD Inspect Revenue Open source 2025-01-01 – 2025-12-31: -115222000 USD Inspect Operating Income Open source 2025-01-01 – 2025-12-31: -104994000 USD Inspect Net Income Open source 2025-01-01 – 2025-12-31: -98694000 USD Inspect Operating Cash Flow Open source 2025-01-01 – 2025-12-31: 607000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 35.9M 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20212021-12-31	Revenue	45785000	Revenue: 45785000 Open source
20222022-12-31	Revenue	31096000	Revenue: 31096000 Open source
20232023-12-31	Revenue	20756000	Revenue: 20756000 Open source
20242024-12-31	Revenue	35584000	Revenue: 35584000 Open source
20252025-12-31	Revenue	35947000	Revenue: 35947000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

1% 2025

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20212021-12-31	Year over year	No prior comparable period	Revenue: 45785000 Open source
20222022-12-31	Year over year	-32.1%	Revenue: 31096000 Open source Revenue: 45785000 Open source
20232023-12-31	Year over year	-33.3%	Revenue: 20756000 Open source Revenue: 31096000 Open source
20242024-12-31	Year over year	71.4%	Revenue: 35584000 Open source Revenue: 20756000 Open source
20252025-12-31	Year over year	1%	Revenue: 35947000 Open source Revenue: 35584000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -320.5% 2025

Net margin -292.1% 2025

Free cash flow margin -276.2% 2025

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20212021-12-31	Operating margin	-179.4%	Operating Income: -82134000 Open source Revenue: 45785000 Open source
20222022-12-31	Operating margin	-416.6%	Operating Income: -129534000 Open source Revenue: 31096000 Open source
20232023-12-31	Operating margin	-669.8%	Operating Income: -139031000 Open source Revenue: 20756000 Open source
20242024-12-31	Operating margin	-336.1%	Operating Income: -119614000 Open source Revenue: 35584000 Open source
20252025-12-31	Operating margin	-320.5%	Operating Income: -115222000 Open source Revenue: 35947000 Open source
20212021-12-31	Net margin	-183.2%	Net Income: -83892000 Open source Revenue: 45785000 Open source
20222022-12-31	Net margin	-412.2%	Net Income: -128175000 Open source Revenue: 31096000 Open source
20232023-12-31	Net margin	-638.3%	Net Income: -132493000 Open source Revenue: 20756000 Open source
20242024-12-31	Net margin	-296%	Net Income: -105316000 Open source Revenue: 35584000 Open source
20252025-12-31	Net margin	-292.1%	Net Income: -104994000 Open source Revenue: 35947000 Open source
20212021-12-31	Free cash flow margin	-192.7%	Revenue: 45785000 Open source Operating Cash Flow: -86965000 Open source Capital Expenditure: 1277000 Open source
20222022-12-31	Free cash flow margin	-358.4%	Revenue: 31096000 Open source Operating Cash Flow: -105939000 Open source Capital Expenditure: 5496000 Open source
20232023-12-31	Free cash flow margin	-523%	Revenue: 20756000 Open source Operating Cash Flow: -106838000 Open source Capital Expenditure: 1708000 Open source
20242024-12-31	Free cash flow margin	-183.6%	Revenue: 35584000 Open source Operating Cash Flow: -65157000 Open source Capital Expenditure: 180000 Open source
20252025-12-31	Free cash flow margin	-276.2%	Revenue: 35947000 Open source Operating Cash Flow: -98694000 Open source Capital Expenditure: 607000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -98.7M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20212021-12-31	Operating cash flow	-86965000	Operating Cash Flow: -86965000 Open source
20222022-12-31	Operating cash flow	-105939000	Operating Cash Flow: -105939000 Open source
20232023-12-31	Operating cash flow	-106838000	Operating Cash Flow: -106838000 Open source
20242024-12-31	Operating cash flow	-65157000	Operating Cash Flow: -65157000 Open source
20252025-12-31	Operating cash flow	-98694000	Operating Cash Flow: -98694000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -99.3M 2025

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20212021-12-31	Free cash flow	-88242000	Operating Cash Flow: -86965000 Open source Capital Expenditure: 1277000 Open source
20222022-12-31	Free cash flow	-111435000	Operating Cash Flow: -105939000 Open source Capital Expenditure: 5496000 Open source
20232023-12-31	Free cash flow	-108546000	Operating Cash Flow: -106838000 Open source Capital Expenditure: 1708000 Open source
20242024-12-31	Free cash flow	-65337000	Operating Cash Flow: -65157000 Open source Capital Expenditure: 180000 Open source
20252025-12-31	Free cash flow	-99301000	Operating Cash Flow: -98694000 Open source Capital Expenditure: 607000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

28.5% 2025

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20212021-12-31	Liabilities / assets	23.1%	Total Liabilities: 117159000 Open source Total Assets: 506765000 Open source
20222022-12-31	Liabilities / assets	32.9%	Total Liabilities: 141606000 Open source Total Assets: 430840000 Open source
20232023-12-31	Liabilities / assets	34.6%	Total Liabilities: 130337000 Open source Total Assets: 376451000 Open source
20242024-12-31	Liabilities / assets	38.2%	Total Liabilities: 133616000 Open source Total Assets: 349602000 Open source
20252025-12-31	Liabilities / assets	28.5%	Total Liabilities: 102488000 Open source Total Assets: 359075000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

7.81× 2025

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20212021-12-31	Current assets / current liabilities	6.36×	Current Assets: 325689000 Open source Current Liabilities: 51246000 Open source
20222022-12-31	Current assets / current liabilities	6.46×	Current Assets: 287557000 Open source Current Liabilities: 44546000 Open source
20232023-12-31	Current assets / current liabilities	6.34×	Current Assets: 271189000 Open source Current Liabilities: 42766000 Open source
20242024-12-31	Current assets / current liabilities	5.71×	Current Assets: 257767000 Open source Current Liabilities: 45177000 Open source
20252025-12-31	Current assets / current liabilities	7.81×	Current Assets: 258110000 Open source Current Liabilities: 33032000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2019 2019-01-01 – 2019-12-31	−USD 34.1 million Exact value Exact value: -34099000 USD 2019-01-01 – 2019-12-31: -34099000 USD Inspect Net Income Open source Share or cite Citation for Net Income · C4 Therapeutics, Inc. · 2019-12-31 C4 Therapeutics, Inc. (edgar:1662579) Net Income: -34099000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T12:03:03Z Snapshot: 45a5b5ed28cca2766bb4405f888912c04c359bf1a8b2472edf40c372df5cfffc Dimensions: Consolidated View: https://fundies.io/companies/edgar/1662579/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -34099000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662579/000156459022006499/cccc-10k_20211231.htm#3954644 Filing: 000156459022006499 The citation records this snapshot. The page link may show a newer release later.	USD 55.61 million Exact value Exact value: 55614000 USD 2019-01-01 – 2019-12-31: 55614000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · C4 Therapeutics, Inc. · 2019-12-31 C4 Therapeutics, Inc. (edgar:1662579) Operating Cash Flow: 55614000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T12:03:03Z Snapshot: 45a5b5ed28cca2766bb4405f888912c04c359bf1a8b2472edf40c372df5cfffc Dimensions: Consolidated View: https://fundies.io/companies/edgar/1662579/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 55614000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662579/000156459022006499/cccc-10k_20211231.htm#2628456 Filing: 000156459022006499 The citation records this snapshot. The page link may show a newer release later.	USD 1.35 million Exact value Exact value: 1349000 USD 2019-01-01 – 2019-12-31: 1349000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · C4 Therapeutics, Inc. · 2019-12-31 C4 Therapeutics, Inc. (edgar:1662579) Capital Expenditure: 1349000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T12:03:03Z Snapshot: 45a5b5ed28cca2766bb4405f888912c04c359bf1a8b2472edf40c372df5cfffc Dimensions: Consolidated View: https://fundies.io/companies/edgar/1662579/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1349000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662579/000156459022006499/cccc-10k_20211231.htm#2650825 Filing: 000156459022006499 The citation records this snapshot. The page link may show a newer release later.	USD 54.27 million Calculation and evidence 55614000 − 1349000 USD Exact free cash flow: 54265000 USD 2019-01-01 – 2019-12-31: 55614000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 1349000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · C4 Therapeutics, Inc. · 2019-12-31 C4 Therapeutics, Inc. (edgar:1662579) Free cash flow: 54265000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T12:03:03Z Snapshot: 45a5b5ed28cca2766bb4405f888912c04c359bf1a8b2472edf40c372df5cfffc Dimensions: Consolidated View: https://fundies.io/companies/edgar/1662579?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 55614000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662579/000156459022006499/cccc-10k_20211231.htm#2628456 Filing: 000156459022006499 Input fundies:CapitalExpenditure: 1349000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662579/000156459022006499/cccc-10k_20211231.htm#2650825 Filing: 000156459022006499 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 66.34 million Exact value Exact value: -66335000 USD 2020-01-01 – 2020-12-31: -66335000 USD Inspect Net Income Open source Share or cite Citation for Net Income · C4 Therapeutics, Inc. · 2020-12-31 C4 Therapeutics, Inc. (edgar:1662579) Net Income: -66335000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T12:03:03Z Snapshot: 45a5b5ed28cca2766bb4405f888912c04c359bf1a8b2472edf40c372df5cfffc Dimensions: Consolidated View: https://fundies.io/companies/edgar/1662579/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -66335000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662579/000156459022006499/cccc-10k_20211231.htm#3952889 Filing: 000156459022006499 The citation records this snapshot. The page link may show a newer release later.	−USD 67.25 million Exact value Exact value: -67249000 USD 2020-01-01 – 2020-12-31: -67249000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · C4 Therapeutics, Inc. · 2020-12-31 C4 Therapeutics, Inc. (edgar:1662579) Operating Cash Flow: -67249000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T12:03:03Z Snapshot: 45a5b5ed28cca2766bb4405f888912c04c359bf1a8b2472edf40c372df5cfffc Dimensions: Consolidated View: https://fundies.io/companies/edgar/1662579/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -67249000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662579/000156459022006499/cccc-10k_20211231.htm#2626602 Filing: 000156459022006499 The citation records this snapshot. The page link may show a newer release later.	USD 650,000 Exact value Exact value: 650000 USD 2020-01-01 – 2020-12-31: 650000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · C4 Therapeutics, Inc. · 2020-12-31 C4 Therapeutics, Inc. (edgar:1662579) Capital Expenditure: 650000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T12:03:03Z Snapshot: 45a5b5ed28cca2766bb4405f888912c04c359bf1a8b2472edf40c372df5cfffc Dimensions: Consolidated View: https://fundies.io/companies/edgar/1662579/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 650000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662579/000156459022006499/cccc-10k_20211231.htm#2649075 Filing: 000156459022006499 The citation records this snapshot. The page link may show a newer release later.	−USD 67.9 million Calculation and evidence -67249000 − 650000 USD Exact free cash flow: -67899000 USD 2020-01-01 – 2020-12-31: -67249000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 650000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · C4 Therapeutics, Inc. · 2020-12-31 C4 Therapeutics, Inc. (edgar:1662579) Free cash flow: -67899000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T12:03:03Z Snapshot: 45a5b5ed28cca2766bb4405f888912c04c359bf1a8b2472edf40c372df5cfffc Dimensions: Consolidated View: https://fundies.io/companies/edgar/1662579?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -67249000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662579/000156459022006499/cccc-10k_20211231.htm#2626602 Filing: 000156459022006499 Input fundies:CapitalExpenditure: 650000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662579/000156459022006499/cccc-10k_20211231.htm#2649075 Filing: 000156459022006499 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 83.89 million Exact value Exact value: -83892000 USD 2021-01-01 – 2021-12-31: -83892000 USD Inspect Net Income Open source Share or cite Citation for Net Income · C4 Therapeutics, Inc. · 2021-12-31 C4 Therapeutics, Inc. (edgar:1662579) Net Income: -83892000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T12:03:03Z Snapshot: 45a5b5ed28cca2766bb4405f888912c04c359bf1a8b2472edf40c372df5cfffc Dimensions: Consolidated View: https://fundies.io/companies/edgar/1662579/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -83892000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662579/000162828023004711/cccc-20221231.htm#2255817 Filing: 000162828023004711 The citation records this snapshot. The page link may show a newer release later.	−USD 86.97 million Exact value Exact value: -86965000 USD 2021-01-01 – 2021-12-31: -86965000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · C4 Therapeutics, Inc. · 2021-12-31 C4 Therapeutics, Inc. (edgar:1662579) Operating Cash Flow: -86965000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T12:03:03Z Snapshot: 45a5b5ed28cca2766bb4405f888912c04c359bf1a8b2472edf40c372df5cfffc Dimensions: Consolidated View: https://fundies.io/companies/edgar/1662579/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -86965000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662579/000162828023004711/cccc-20221231.htm#1440990 Filing: 000162828023004711 The citation records this snapshot. The page link may show a newer release later.	USD 1.28 million Exact value Exact value: 1277000 USD 2021-01-01 – 2021-12-31: 1277000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · C4 Therapeutics, Inc. · 2021-12-31 C4 Therapeutics, Inc. (edgar:1662579) Capital Expenditure: 1277000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T12:03:03Z Snapshot: 45a5b5ed28cca2766bb4405f888912c04c359bf1a8b2472edf40c372df5cfffc Dimensions: Consolidated View: https://fundies.io/companies/edgar/1662579/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1277000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662579/000162828023004711/cccc-20221231.htm#1448872 Filing: 000162828023004711 The citation records this snapshot. The page link may show a newer release later.	−USD 88.24 million Calculation and evidence -86965000 − 1277000 USD Exact free cash flow: -88242000 USD 2021-01-01 – 2021-12-31: -86965000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 1277000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · C4 Therapeutics, Inc. · 2021-12-31 C4 Therapeutics, Inc. (edgar:1662579) Free cash flow: -88242000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T12:03:03Z Snapshot: 45a5b5ed28cca2766bb4405f888912c04c359bf1a8b2472edf40c372df5cfffc Dimensions: Consolidated View: https://fundies.io/companies/edgar/1662579?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -86965000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662579/000162828023004711/cccc-20221231.htm#1440990 Filing: 000162828023004711 Input fundies:CapitalExpenditure: 1277000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662579/000162828023004711/cccc-20221231.htm#1448872 Filing: 000162828023004711 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 128.18 million Exact value Exact value: -128175000 USD 2022-01-01 – 2022-12-31: -128175000 USD Inspect Net Income Open source Share or cite Citation for Net Income · C4 Therapeutics, Inc. · 2022-12-31 C4 Therapeutics, Inc. (edgar:1662579) Net Income: -128175000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T12:03:03Z Snapshot: 45a5b5ed28cca2766bb4405f888912c04c359bf1a8b2472edf40c372df5cfffc Dimensions: Consolidated View: https://fundies.io/companies/edgar/1662579/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -128175000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662579/000162828024006144/cccc-20231231.htm#1933070 Filing: 000162828024006144 The citation records this snapshot. The page link may show a newer release later.	−USD 105.94 million Exact value Exact value: -105939000 USD 2022-01-01 – 2022-12-31: -105939000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · C4 Therapeutics, Inc. · 2022-12-31 C4 Therapeutics, Inc. (edgar:1662579) Operating Cash Flow: -105939000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T12:03:03Z Snapshot: 45a5b5ed28cca2766bb4405f888912c04c359bf1a8b2472edf40c372df5cfffc Dimensions: Consolidated View: https://fundies.io/companies/edgar/1662579/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -105939000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662579/000162828024006144/cccc-20231231.htm#1314686 Filing: 000162828024006144 The citation records this snapshot. The page link may show a newer release later.	USD 5.5 million Exact value Exact value: 5496000 USD 2022-01-01 – 2022-12-31: 5496000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · C4 Therapeutics, Inc. · 2022-12-31 C4 Therapeutics, Inc. (edgar:1662579) Capital Expenditure: 5496000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T12:03:03Z Snapshot: 45a5b5ed28cca2766bb4405f888912c04c359bf1a8b2472edf40c372df5cfffc Dimensions: Consolidated View: https://fundies.io/companies/edgar/1662579/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 5496000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662579/000162828024006144/cccc-20231231.htm#1320177 Filing: 000162828024006144 The citation records this snapshot. The page link may show a newer release later.	−USD 111.44 million Calculation and evidence -105939000 − 5496000 USD Exact free cash flow: -111435000 USD 2022-01-01 – 2022-12-31: -105939000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 5496000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · C4 Therapeutics, Inc. · 2022-12-31 C4 Therapeutics, Inc. (edgar:1662579) Free cash flow: -111435000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T12:03:03Z Snapshot: 45a5b5ed28cca2766bb4405f888912c04c359bf1a8b2472edf40c372df5cfffc Dimensions: Consolidated View: https://fundies.io/companies/edgar/1662579?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -105939000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662579/000162828024006144/cccc-20231231.htm#1314686 Filing: 000162828024006144 Input fundies:CapitalExpenditure: 5496000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662579/000162828024006144/cccc-20231231.htm#1320177 Filing: 000162828024006144 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 132.49 million Exact value Exact value: -132493000 USD 2023-01-01 – 2023-12-31: -132493000 USD Inspect Net Income Open source Share or cite Citation for Net Income · C4 Therapeutics, Inc. · 2023-12-31 C4 Therapeutics, Inc. (edgar:1662579) Net Income: -132493000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T12:03:03Z Snapshot: 45a5b5ed28cca2766bb4405f888912c04c359bf1a8b2472edf40c372df5cfffc Dimensions: Consolidated View: https://fundies.io/companies/edgar/1662579/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -132493000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662579/000162828025008433/cccc-20241231.htm#1993544 Filing: 000162828025008433 The citation records this snapshot. The page link may show a newer release later.	−USD 106.84 million Exact value Exact value: -106838000 USD 2023-01-01 – 2023-12-31: -106838000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · C4 Therapeutics, Inc. · 2023-12-31 C4 Therapeutics, Inc. (edgar:1662579) Operating Cash Flow: -106838000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T12:03:03Z Snapshot: 45a5b5ed28cca2766bb4405f888912c04c359bf1a8b2472edf40c372df5cfffc Dimensions: Consolidated View: https://fundies.io/companies/edgar/1662579/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -106838000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662579/000162828025008433/cccc-20241231.htm#1339262 Filing: 000162828025008433 The citation records this snapshot. The page link may show a newer release later.	USD 1.71 million Exact value Exact value: 1708000 USD 2023-01-01 – 2023-12-31: 1708000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · C4 Therapeutics, Inc. · 2023-12-31 C4 Therapeutics, Inc. (edgar:1662579) Capital Expenditure: 1708000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T12:03:03Z Snapshot: 45a5b5ed28cca2766bb4405f888912c04c359bf1a8b2472edf40c372df5cfffc Dimensions: Consolidated View: https://fundies.io/companies/edgar/1662579/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1708000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662579/000162828025008433/cccc-20241231.htm#1344722 Filing: 000162828025008433 The citation records this snapshot. The page link may show a newer release later.	−USD 108.55 million Calculation and evidence -106838000 − 1708000 USD Exact free cash flow: -108546000 USD 2023-01-01 – 2023-12-31: -106838000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 1708000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · C4 Therapeutics, Inc. · 2023-12-31 C4 Therapeutics, Inc. (edgar:1662579) Free cash flow: -108546000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T12:03:03Z Snapshot: 45a5b5ed28cca2766bb4405f888912c04c359bf1a8b2472edf40c372df5cfffc Dimensions: Consolidated View: https://fundies.io/companies/edgar/1662579?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -106838000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662579/000162828025008433/cccc-20241231.htm#1339262 Filing: 000162828025008433 Input fundies:CapitalExpenditure: 1708000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662579/000162828025008433/cccc-20241231.htm#1344722 Filing: 000162828025008433 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 105.32 million Exact value Exact value: -105316000 USD 2024-01-01 – 2024-12-31: -105316000 USD Inspect Net Income Open source Share or cite Citation for Net Income · C4 Therapeutics, Inc. · 2024-12-31 C4 Therapeutics, Inc. (edgar:1662579) Net Income: -105316000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T12:03:03Z Snapshot: 45a5b5ed28cca2766bb4405f888912c04c359bf1a8b2472edf40c372df5cfffc Dimensions: Consolidated View: https://fundies.io/companies/edgar/1662579/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -105316000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662579/000162828026012000/cccc-20251231.htm#1989267 Filing: 000162828026012000 The citation records this snapshot. The page link may show a newer release later.	−USD 65.16 million Exact value Exact value: -65157000 USD 2024-01-01 – 2024-12-31: -65157000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · C4 Therapeutics, Inc. · 2024-12-31 C4 Therapeutics, Inc. (edgar:1662579) Operating Cash Flow: -65157000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T12:03:03Z Snapshot: 45a5b5ed28cca2766bb4405f888912c04c359bf1a8b2472edf40c372df5cfffc Dimensions: Consolidated View: https://fundies.io/companies/edgar/1662579/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -65157000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662579/000162828026012000/cccc-20251231.htm#1305062 Filing: 000162828026012000 The citation records this snapshot. The page link may show a newer release later.	USD 180,000 Exact value Exact value: 180000 USD 2024-01-01 – 2024-12-31: 180000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · C4 Therapeutics, Inc. · 2024-12-31 C4 Therapeutics, Inc. (edgar:1662579) Capital Expenditure: 180000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T12:03:03Z Snapshot: 45a5b5ed28cca2766bb4405f888912c04c359bf1a8b2472edf40c372df5cfffc Dimensions: Consolidated View: https://fundies.io/companies/edgar/1662579/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 180000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662579/000162828026012000/cccc-20251231.htm#1310461 Filing: 000162828026012000 The citation records this snapshot. The page link may show a newer release later.	−USD 65.34 million Calculation and evidence -65157000 − 180000 USD Exact free cash flow: -65337000 USD 2024-01-01 – 2024-12-31: -65157000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 180000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · C4 Therapeutics, Inc. · 2024-12-31 C4 Therapeutics, Inc. (edgar:1662579) Free cash flow: -65337000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T12:03:03Z Snapshot: 45a5b5ed28cca2766bb4405f888912c04c359bf1a8b2472edf40c372df5cfffc Dimensions: Consolidated View: https://fundies.io/companies/edgar/1662579?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -65157000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662579/000162828026012000/cccc-20251231.htm#1305062 Filing: 000162828026012000 Input fundies:CapitalExpenditure: 180000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662579/000162828026012000/cccc-20251231.htm#1310461 Filing: 000162828026012000 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−USD 104.99 million Exact value Exact value: -104994000 USD 2025-01-01 – 2025-12-31: -104994000 USD Inspect Net Income Open source Share or cite Citation for Net Income · C4 Therapeutics, Inc. · 2025-12-31 C4 Therapeutics, Inc. (edgar:1662579) Net Income: -104994000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T12:03:03Z Snapshot: 45a5b5ed28cca2766bb4405f888912c04c359bf1a8b2472edf40c372df5cfffc Dimensions: Consolidated View: https://fundies.io/companies/edgar/1662579/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -104994000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662579/000162828026012000/cccc-20251231.htm#1988493 Filing: 000162828026012000 The citation records this snapshot. The page link may show a newer release later.	−USD 98.69 million Exact value Exact value: -98694000 USD 2025-01-01 – 2025-12-31: -98694000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · C4 Therapeutics, Inc. · 2025-12-31 C4 Therapeutics, Inc. (edgar:1662579) Operating Cash Flow: -98694000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T12:03:03Z Snapshot: 45a5b5ed28cca2766bb4405f888912c04c359bf1a8b2472edf40c372df5cfffc Dimensions: Consolidated View: https://fundies.io/companies/edgar/1662579/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -98694000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662579/000162828026012000/cccc-20251231.htm#1304410 Filing: 000162828026012000 The citation records this snapshot. The page link may show a newer release later.	USD 607,000 Exact value Exact value: 607000 USD 2025-01-01 – 2025-12-31: 607000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · C4 Therapeutics, Inc. · 2025-12-31 C4 Therapeutics, Inc. (edgar:1662579) Capital Expenditure: 607000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T12:03:03Z Snapshot: 45a5b5ed28cca2766bb4405f888912c04c359bf1a8b2472edf40c372df5cfffc Dimensions: Consolidated View: https://fundies.io/companies/edgar/1662579/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 607000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662579/000162828026012000/cccc-20251231.htm#1309902 Filing: 000162828026012000 The citation records this snapshot. The page link may show a newer release later.	−USD 99.3 million Calculation and evidence -98694000 − 607000 USD Exact free cash flow: -99301000 USD 2025-01-01 – 2025-12-31: -98694000 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 607000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · C4 Therapeutics, Inc. · 2025-12-31 C4 Therapeutics, Inc. (edgar:1662579) Free cash flow: -99301000 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T12:03:03Z Snapshot: 45a5b5ed28cca2766bb4405f888912c04c359bf1a8b2472edf40c372df5cfffc Dimensions: Consolidated View: https://fundies.io/companies/edgar/1662579?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -98694000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662579/000162828026012000/cccc-20251231.htm#1304410 Filing: 000162828026012000 Input fundies:CapitalExpenditure: 607000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662579/000162828026012000/cccc-20251231.htm#1309902 Filing: 000162828026012000 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

48 filings · 1,841 latest values · 1,841 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001662579, 1662579, CCCC, edgar:1662579

Also known as C4 THERAPEUTICS, INC., C4 Therapeutics, Inc.

C4 Therapeutics, Inc.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation